Approaches to identifying synthetic lethal interactions in cancer

Yale Journal of Biology and Medicine

Volumn 88, Issue 2, 2015, Pages 145-155

  Thompson, Jordan M ^a   Nguyen, Quy H ^a   Singh, Manpreet ^a   Razorenova, Olga V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antitumor; Cancer; Computational screen; CRISPR library; CRISPR screen; DAISY; Drug discovery; Drug screening assays; Library screens; Neoplasms; shRNA library; shRNA screen; siRNA library; siRNA screen; Synthetic lethal interactions; Synthetic lethality

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ANTINEOPLASTIC AGENT;

CANCER CELL LINE; CANCER SURVIVAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; EPIGENETICS; GENE DELETION; GENE FUNCTION; GENE INTERACTION; GENE LOSS; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR LIBRARY; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHENOTYPE; QUALITY OF LIFE; REVIEW; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; ANIMAL; APOPTOSIS; DRUG DEVELOPMENT; DRUG EFFECTS; GENE THERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DISCOVERY; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84930171432     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21(24):3214-31.
2. weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006;3(8):448-57.
3. Hanahan D, weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
4. Reddy A, Kaelin WG Jr. Using cancer genetics to guide the selection of anticancer drug targets. Curr Opin Pharmacol. 2002;2(4):366-73.
5. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193-204.
6. Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014;105(4):370-88.
7. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008;123(6):1227-39.
8. Hartman J, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science. 2001;1001(291):1001-4.
9. Boone C, Bussey H, Andrews BJ. Exploring genetic interactions and networks with yeast. Nat Rev Genet. 2007;8(6):437-49.
10. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011;10(5):351-64.
11. Steckel M, Molina-Arcas M, weigelt B, Marani M, warne PH, Kuznetsov H, et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 2012;22(8):1227-45.
12. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137(5):835-48.
13. Mair B, Kubicek S, Nijman SMB. Exploiting epigenetic vulnerabilities for cancer therapeutics. Trends Pharmacol Sci. 2014;35(3):136-45.
14. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 2010;70(20):8045-54.
15. Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA. 2011;108(24):9851-6.
16. Bryant H, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ri-bose) polymerase. Nature. 2005;434(7035):913-7.
17. Farmer H, Mccabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21.
18. Ellisen L. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell. 2011;19(2):165-7.
19. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):229-39.
20. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382-92.
21. Ledermann J, Harter P, Gourley C, Friedlander M, vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61.
22. Leibowitz B, Qiu W, Buchanan ME, Zou F, vernon P, Moyer MP, et al. BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflamma-tory drugs. Proc Natl Acad Sci USA. 2014;111(46):16520-5.
23. Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Gi-accia AJ. A molecule targeting vHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008;14(1):90-102.
24. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai Ew, Banh A, et al. Targeting GLUT1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011;3(94):94ra70.
25. Jacquemont C, Simon JA, D’Andrea AD, Taniguchi T. Nonspecific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer. 2012;11:26.
26. Gordan J, Lal P, Dondeti V, Letrero R. HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic vHL-Deficient Clear Cell Renal Carcinoma. Cancer Cell. 2008;14(6):435-46.
27. Rabik C, Dolan M. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9-23.
28. Dhillon K, Swisher E, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci. 2011;102(4):663-9.
29. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502-16.
30. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2(4):277-88.
31. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5(11):876-85.
32. Kranz D, Boutros M. A synthetic lethal screen identifies FAT 1 as an antagonist of caspase-8 in extrinsic apoptosis. EMBO J. 2014;33(3):181-97.
33. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789-802.
34. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2013;8(1):82-95.
35. Josse R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, et al. The ATR inhibitors vE-821 and vX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014;74(23):6968-79.
36. Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim S Y, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009;137(5):821-34.
37. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci USA. 2014;111(8):3128-33. t
38. Etemadmoghadam D, weir BA, Au-Yeung G, Alsop K, Mitchell G, George J, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci USA. 2013;110(48):19489-94.
39. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Löhrs U, et al. Analysis of Gene Amplification and Prognostic Markers in Ovarian Cancer Using Comparative Genomic Hybridization for Microarrays and Immunohistochemical Analysis for Tissue Microarrays. Am J Clin Pathol. 2006;126(1):101-9.
40. Etemadmoghadam D, Beroukhim R. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009;15(4):1417-27.
41. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther. 2003;2(4 Suppl 1):S38-47.
42. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-28.
43. Bai J, Mei P, Zhang C, Chen F, Li C, Pan Z, et al. BRG1 is a prognostic marker and potential therapeutic target in human breast cancer. PLoS One. 2013;8(3):e59772.
44. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295-308.
45. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
46. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS onco-genes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761-74.
47. Jansen R, Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43(6):1565-75.
48. wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482(7385):331-8.
49. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014;32(4):347-55.
50. Koike-Yusa H, Li Y, Tan E-P, velasco-Herrera MDC, Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol. 2014;32(3):267-73.
51. Szappanos B, Kovács K, Szamecz B, Honti F, Costanzo M, Baryshnikova A, et al. An integrated approach to characterize genetic interaction networks in yeast metabolism. Nat Genet. 2011;43(7):656-62.
52. Jerby-Arnon L, Pfetzer N, waldman YY, McGarry L, James D, Shanks E, et al. Predicting Cancer-Specific vulnerability via Data-Driven Detection of Synthetic Lethality. Cell. 2014;158(5):1199-209.